-+ 0.00%
-+ 0.00%
-+ 0.00%
Elevance Health (ELV) Stock Still Looks Undervalued Despite Its 29% Run
Share
Listen to the news

Elevance Health has delivered a 29.2% gain over the past year, even as the stock has slipped in recent weeks, which puts fresh focus on whether that climb is supported by the earnings behind the ticker. With fresh headlines around Medicaid margins and fraud litigation, the real question for investors is how well the current share price lines up with the profits the insurer is generating today.

  • The stock is up 29.2% over the past year, so anyone looking at Elevance Health now is effectively asking whether that advance already reflects what its earnings can justify.
  • Management is emphasizing a path to Medicaid margin recovery and higher adjusted earnings in the coming years, which can shape how much investors are willing to pay for each dollar of current profit.
  • There is a second opinion on Elevance Health worth weighing. See what analysts think Elevance Health's shares could be worth.

The stock's next move may depend on whether Elevance Health's current earnings profile is enough to support where the share price sits today.

If headlines around Elevance Health have you reassessing what you pay for each dollar of profit, a focused stock screen built around earnings quality such as 35 high quality undervalued stocks may be useful.

Is Elevance Health a Bargain on Earnings?

P/E fits Elevance Health because earnings remain the main yardstick investors use for managed care businesses with steady cash generation. On this metric, the stock trades at about 16.9x earnings, compared with roughly 25.1x for the broader healthcare sector and around 28.5x for its peer group. That is a clear discount to both the industry and similar insurers that the market tends to compare it with.

The fair multiple implied by a more tailored model that considers Elevance Health’s growth profile, profitability, size and risk suggests the current P/E sits below where it might trade if it were priced in line with those fundamentals. Because management is dealing with issues such as the Medicaid margin reset and the fraud litigation highlighted this year, the gap signals that investors are still baking in a degree of caution even though the earnings line already supports a lower P/E than peers. Explore the numbers behind Elevance Health's P/E valuation.

NYSE:ELV P/E Ratio as at Nov 2026
NYSE:ELV P/E Ratio as at Nov 2026

The Elevance Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Elevance Health valuation puzzle leaves off. They spell out which specific paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than it is today. Each one links its number to a clear view on how Elevance Health's profitability and risk profile might evolve, which you can revisit on the Community page as fresh information comes through.

One of the top narratives on Elevance Health: 6% undervalued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"Bearish analysts expect Elevance Health to struggle to offset elevated system costs in government-backed plans as Medicaid margins remain under pressure..."

Discover why this Narrative puts Elevance Health at 6% undervalued.

One more Elevance Health piece to check before you decide the stock is cheap or expensive

Everything so far has focused on what Elevance Health earns today, yet analyst views on where profits could land a few years from now provide a different reference point to compare with the current price. Explore where analysts expect Elevance Health to be in a few years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending